ARKG vs XBI

Key Takeaways

• ARKG is an actively managed thematic ETF targeting the genomics revolution with a concentrated portfolio of approximately 35 holdings and a higher expense ratio of 0.75%.
• XBI is a passively managed ETF tracking an equal-weighted S&P Biotechnology Select Industry Index, offering broader diversification across roughly 140 holdings at a lower expense ratio of 0.35%.
• Both ETFs provide exposure to the biotechnology and healthcare sectors but differ significantly in strategy, with ARKG emphasizing disruptive genomics technologies and XBI delivering balanced representation across the broader biotech industry.
• Structural differences include ARKG’s active stock selection versus XBI’s rules-based equal-weighting methodology, which influences concentration risk and rebalancing frequency.
• Investors seeking cost efficiency and diversified sector exposure may prefer XBI, while those targeting specific thematic growth in gene editing and related fields may consider ARKG despite higher fees.
• Both funds operate in a high-volatility sector sensitive to regulatory developments, clinical trial outcomes, and macroeconomic factors such as interest rate expectations.

Introduction

ARKG and XBI both target the biotechnology space, yet they employ distinct approaches to deliver exposure within the healthcare sector. ARKG pursues an active, thematic strategy centered on genomic innovation, while XBI offers passive, equal-weighted access to a wide array of biotech companies. These ETFs serve as relevant alternatives for investors seeking growth opportunities in life sciences rather than direct competitors. Comparing them helps clarify trade-offs in cost, diversification, and strategic focus amid ongoing advancements in personalized medicine and biotech innovation.

ARK Genomic Revolution ETF (ARKG) Overview

The ARK Genomic Revolution ETF is an actively managed exchange-traded fund launched in 2014 by ARK Investment Management. It seeks long-term capital growth by investing primarily in equity securities of companies involved in the genomics revolution, including gene editing, CRISPR technologies, and related fields across healthcare and other sectors. The fund typically holds 33 to 40 securities, resulting in a concentrated portfolio where the top 10 holdings often represent over 60% of assets. Representative top positions include Twist Bioscience (TWST), CRISPR Therapeutics (CRSP), and Tempus AI (TEM). Sector allocation centers heavily on healthcare. The expense ratio stands at 0.75%. As an actively managed thematic product, it does not track a specific index and features discretionary rebalancing based on the manager’s research.

SPDR S&P Biotech ETF (XBI) Overview

The SPDR S&P Biotech ETF is a passively managed exchange-traded fund launched in 2006 by State Street Global Advisors. It seeks to track the performance of the S&P Biotechnology Select Industry Index before fees and expenses. The index employs a modified equal-weight methodology across U.S.-listed biotechnology companies engaged in research, development, and commercialization of biotech products. The fund typically holds 130 to 150 securities, providing broad diversification with the top 10 holdings comprising around 16% of assets. Holdings are spread across numerous small-, mid-, and large-cap biotech firms. Sector allocation is almost entirely healthcare. The expense ratio is 0.35%. The fund rebalances periodically to maintain equal weights within the index methodology.

Industry and Thematic Backdrop

The biotechnology sector encompasses companies developing therapies, diagnostics, and tools based on biological processes, with particular emphasis on genomics and personalized medicine. Key catalysts include ongoing clinical advancements, regulatory approvals from agencies such as the U.S. Food and Drug Administration, and capital flows into innovative platforms. Macroeconomic drivers such as interest rate environments influence funding availability for research-intensive firms, while sector risks involve high failure rates in clinical trials, patent expirations, and policy changes affecting drug pricing and reimbursement. Both ETFs operate within this dynamic landscape, where innovation cycles and capital allocation decisions shape long-term opportunities.

Performance and Positioning Comparison

In recent market cycles, ARKG’s concentrated active approach has led to higher volatility compared with XBI’s equal-weighted passive structure, reflecting differences in sensitivity to individual stock events and sector rotation. XBI’s broader diversification has historically provided more balanced exposure during periods of uneven biotech performance driven by earnings cycles or shifts in investor sentiment toward growth versus value. Relative positioning favors XBI for investors prioritizing cost efficiency and reduced single-stock risk, while ARKG positions for potential outperformance in genomics-specific themes during periods of strong innovation momentum.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to enhance your research process.

Tickeron AI Verdict

Based on observable structural factors, Tickeron’s AI would currently assign a higher probability of favor to XBI due to its lower expense ratio, greater diversification across holdings, and rules-based equal-weighting methodology that supports consistent sector exposure with reduced concentration risk. ARKG’s active thematic focus offers distinct potential but carries higher costs and volatility that may not align as favorably under current efficiency and risk-adjusted criteria.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations